Molecular virology and the development of resistant mutants: implications for therapy
- PMID: 16103977
- DOI: 10.1055/s-2005-915645
Molecular virology and the development of resistant mutants: implications for therapy
Abstract
Two of the key events in the viral life cycle of the hepatitis B virus (HBV) involve (1) generation from genomic DNA of the covalently closed circular DNA transcriptional template and (2) reverse transcription of the viral pregenomic RNA to form the HBV DNA genome. Because the virus employs reverse transcription to copy its genome, mutant viral genomes are found frequently. Particular selection pressures, both endogenous (host immune clearance) and exogenous (vaccines and antivirals), readily select out these escape mutants. The introduction of nucleoside/nucleotide analogue therapy has seen the emergence of drug resistance as the major factor limiting drug efficacy. The development of drug resistance is not unexpected if viral replication continues in the setting of ongoing treatment, especially monotherapy. Thus, prevention of resistance requires the adoption of strategies that effectively control virus replication.
Similar articles
-
Major causes of antiviral drug resistance and implications for treatment of hepatitis B virus monoinfection and coinfection with HIV.Antivir Ther. 2007;12 Suppl 3:H15-23. Antivir Ther. 2007. PMID: 18284179 Review.
-
Molecular genetics of HBV infection.Antivir Ther. 2010;15 Suppl 3:3-14. doi: 10.3851/IMP1619. Antivir Ther. 2010. PMID: 21041899 Review.
-
Molecular genesis of drug-resistant and vaccine-escape HBV mutants.Antivir Ther. 2010;15(3 Pt B):451-61. doi: 10.3851/IMP1499. Antivir Ther. 2010. PMID: 20516565 Review.
-
The hepatitis B virus and common mutants.Semin Liver Dis. 2003 Feb;23(1):5-20. doi: 10.1055/s-2003-37587. Semin Liver Dis. 2003. PMID: 12616447 Review.
-
Molecular virology of hepatitis B virus.Semin Liver Dis. 2004;24 Suppl 1:3-10. doi: 10.1055/s-2004-828672. Semin Liver Dis. 2004. PMID: 15192795 Review.
Cited by
-
Molecular evolution of hepatitis B virus over 25 years.J Virol. 2006 Nov;80(21):10307-14. doi: 10.1128/JVI.00996-06. J Virol. 2006. PMID: 17041211 Free PMC article.
-
A combination treatment of entecavir and early-phase corticosteroid in severe exacerbation of chronic hepatitis B.World J Gastroenterol. 2009 Apr 7;15(13):1650-2. doi: 10.3748/wjg.15.1650. World J Gastroenterol. 2009. PMID: 19340912 Free PMC article.
-
New universal primers for genotyping and resistance detection of low HBV DNA levels.Medicine (Baltimore). 2016 Aug;95(33):e4618. doi: 10.1097/MD.0000000000004618. Medicine (Baltimore). 2016. PMID: 27537600 Free PMC article.
-
Detection of rtN236T mutation associated with adefovir dipivoxil resistance in Hepatitis B infected patients with YMDD mutations in Tehran.Iran J Microbiol. 2013 Mar;5(1):76-80. Iran J Microbiol. 2013. PMID: 23467016 Free PMC article.
-
Randomized controlled study investigating viral suppression and serological response following pre-S1/pre-S2/S vaccine therapy combined with lamivudine treatment in HBeAg-positive patients with chronic hepatitis B.Antimicrob Agents Chemother. 2009 Dec;53(12):5134-40. doi: 10.1128/AAC.00276-09. Epub 2009 Sep 21. Antimicrob Agents Chemother. 2009. PMID: 19770281 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources